Abstract:Background: Cancer is the most prevalent disease seen nowadays. Thymidine phosphorylase (TP) is an angiogenic enzyme that is overexpressed in many solid tumors. Over the years, Thymidine phosphorylase has emerged as a novel target for anticancer drug development as an inhibitor. Objective: To design novel oxadiazole-isatin pharmacophore containing molecules and to explore their structural requirements related to the anticancer activity. Methods: Pharmacophore optimisation was carried out for oxadiazole-isatin hybrid molecules using molecular modeling studies (2D and 3D QSAR). Further, the new chemical entities were designed using combilib tool of V life software. To have a better understanding of the binding interactions, the newly designed molecules were docked. To achieve a drug-like pharmacokinetic profile, molecules were also tested for ADME prediction. Results: For Two-Dimensional Quantitative Structure-Activity Relationship (2D-QSAR) model was generated using the multiple regression method with r2 = 0.84 and q2 = 0.76. Three-Dimensional Quantitative Structure-Activity Relationship (3D-QSAR) model was obtained by simulated annealing k nearest near (SA kNN) method with q2 = 0.8099. Molecular docking studies showed promising results. The compound with the best dock score and the best fit to the active site pocket of the thymidylate phosphorylase enzyme was found to be compound 5. The compounds have notable absorption, distribution, metabolism, and excretion (ADME) properties that can be predicted to assure a drug-like pharmacokinetic profile. Conclusion: One of the most successful and fast-increasing methodologies is molecular modeling. It not only aids in the prediction of specific target compounds but also aids in the cost reduction of valuable substances. The successful use of molecular modeling was done in this study, with caution taken to avoid any chance co-relation. Optimised pharmacophore was obtained and new chemical entities were designed. Docking studies revealed that Molecule 5 have shown better H-bond interaction with Lys 221 and Thr 151 with bond distances 2.0  and 1.8  which is the most active molecule. ADME tests discovered that the majority of the newly designed compounds were within a reasonable range as required in a drug like pharmacokinetic profile. Molecules 2, 4, 5, 6 can be considered as a lead for future synthesis and biological screening.

In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs

CADD Methods for Developing Novel Compounds Synthesized to Inhibit Tyrosine Kinase Receptors

Rational Design of Covalent Kinase Inhibitors by an Integrated Computational Workflow (Kin-Cov)

Using the Structural Kinome to Systematize Kinase Drug Discovery

Design strategies, structure activity relationship and mechanistic insights for purines as kinase inhibitors

An Updated Review on Developing Small Molecule Kinase Inhibitors Using Computer-Aided Drug Design Approaches

Docking of Protein Kinase B Inhibitors: Implications in the Structure-Based Optimization of A Novel Scaffold

The design of TOPK inhibitors using structure-based pharmacophore modeling and molecular docking based on an MD-refined homology model

Optimization Techniques for Novel C-Met Kinase Inhibitors

Kinase Drug Discovery: Impact of Open Science and Artificial Intelligence

A Rational Approach to Anticancer Drug Design: 2D and 3D- QSAR, Molecular Docking and Prediction of ADME Properties Using Silico Studies of Thymidine Phosphorylase Inhibitors

Computational Approaches to the Rational Design of Tubulin-Targeting Agents

Chemical analogue based drug design for cancer treatment targeting PI3K: integrating machine learning and molecular modeling

Structure-Activity Relationship Study and Design Strategies of Hydantoin, Thiazolidinedione, and Rhodanine-Based Kinase Inhibitors: A Two-Decade Review

Integrated Molecular Modeling and Machine Learning for Drug Design

In silico design of novel CDK2 inhibitors through QSAR, ADMET, molecular docking and molecular dynamics simulation studies

FDA-approved small molecule kinase inhibitors for cancer treatment (2001-2015): Medical indication, structural optimization, and binding mode Part I

Structure-based drug design: From nucleic acid to membrane protein targets

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives

An in silico approach to identify novel and potential Akt1 (protein kinase B-alpha) inhibitors as anticancer drugs

Compounds Designs of CK2α Inhibitors Derived from Virtual Screening Hit Compounds by Computational Chemistry with Crystallography